GRAIL Inc (GRAL) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...
Despite a significant net loss, GRAIL Inc (GRAL) reports strong revenue growth and strategic collaborations, setting the stage for future advancements.
Grail projects FDA submission completion for Galleri by H1 2026 with expanded scalability
Q4 2024 Management View CEO Bob Ragusa highlighted 2024 as a transformative year for the company, noting the separation from Illumina and the launch of public trading in June. He mentioned that U.S.
USA News Group: Investors Eye Biotech Sector as Cancer Therapy Market Surges
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News Commentary - Amid the excitement surrounding ...
Investors Eye Biotech Sector as Cancer Therapy Market Surges
Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.
Orange County Business Journal5d
Medical Diagnostics and Testing Cos. Fall 2.9% in Local Employees
The local sector of test makers, specialized equipment manufacturers and testing product suppliers remain invested in their ...